aex-1 Antibody

Anion-Exchange Chromatography (AEX) in Antibody Purification

AEX is a critical step in therapeutic antibody manufacturing, particularly for removing impurities such as host cell proteins (HCPs), DNA, and endotoxins . Key features include:

• Flow-Through Mode: Most human antibodies (pI ~8–9) do not bind to AEX resins at neutral pH, allowing them to pass through while charged impurities bind .

• Virus Clearance: Validated for robust viral clearance due to strong binding of negatively charged viral particles .

• Salt-Tolerant Resins: Enable polishing steps under high conductivity conditions, improving impurity removal without compromising antibody stability .

Table 1: AEX Performance Metrics for Antibody Purification

Antibody Characterization Using AEX

AEX resolves charge variants (acidic/basic species) caused by post-translational modifications:

• Acidic Species: Include deamidation, glycation, or trisulfide bonds, eluting later in AEX .

• Basic Species: Often caused by C-terminal lysine variants, eluting earlier .

Example: In recombinant IgG2, trisulfide-bonded antibodies elute later than the main peak, correlating with acidic species .

Case Studies of Antibodies Purified via AEX

• ABX-EGF (Panitumumab): A fully human anti-EGFR monoclonal antibody purified using AEX. Clinical trials demonstrated its safety profile, with dose-dependent acneiform rash as a pharmacodynamic marker .

• Anti-PD-1 Antibodies: Used in adjuvant settings for melanoma, with AEX aiding in aggregate removal during manufacturing .

Table 2: Analytical Parameters for Antibody Charge Variants

Hypothetical Context for "AEX-1 Antibody"

If "AEX-1" refers to a model antibody used in process development (e.g., Table 1 in ), its attributes might include:

• Subtype: Human IgG1 (pI ~8.3)

• Impurity Profile: ~80 ng/mg HCP post-Protein A capture .

• Applications: Salt-tolerant AEX optimization for flow-through polishing .

Limitations and Research Gaps

No direct references to "AEX-1 Antibody" were identified in the provided sources. Future studies could explore:

• Custom AEX resins for novel antibody formats (e.g., bispecifics) .

• High-throughput screening for charge variant mitigation .